Inhibition of C1-Ten PTPase activity reduces insulin resistance through IRS-1 and AMPK pathways

Area of Science:

• Biochemistry
• Metabolic Disorders
• Pharmacology

Background:

• Insulin resistance is a primary cause of type 2 diabetes.
• AMP-activated protein kinase (AMPK) activation and increased insulin receptor substrate-1 (IRS-1) are key therapeutic targets.
• Dual targeting of AMPK and IRS-1 may offer an effective treatment strategy for diabetes.

Purpose of the Study:

• To investigate 15,16-dihydrotanshinone I (DHTS) as a potential therapeutic agent for insulin resistance.
• To explore the role of C1-Ten protein tyrosine phosphatase in regulating AMPK and IRS-1.
• To evaluate DHTS's efficacy in improving glucose tolerance and metabolic health.

Main Methods:

• Utilized DHTS as a C1-Ten protein tyrosine phosphatase inhibitor.
• Assessed the impact of DHTS on IRS-1 stability and AMPK activity.
• Evaluated glucose tolerance and muscle atrophy in relevant models.

Main Results:

• DHTS treatment increased IRS-1 stability.
• DHTS administration improved glucose tolerance and reduced muscle atrophy.
• DHTS was identified as a C1-Ten inhibitor, revealing C1-Ten's role in AMPK inhibition via IRS-1 regulation.

Conclusions:

• C1-Ten inhibition by DHTS presents a novel therapeutic strategy for insulin resistance.
• DHTS demonstrates potential for treating metabolic syndrome through dual targeting of IRS-1 and AMPK.
• This research offers a new pathway for developing diabetes therapeutics.